| |
TheraNova, LLC Technologies >> Incubated
 | | | |
The following is a short profile of several of TheraNova's patent pending technologies that have not yet been spun out into a venture. Further information is available upon request after completion of a Nondisclosure Agreement (NDA).
Click HERE to download TheraNova's standard NDA.
| |
Low
Frequency Induction Therapy (LFIT)
Seeking licensing or development partner |
Arthritis was reported to affect 15%
of Americans, or an estimated 40 million people, in 1995. By the year
2020, arthritic conditions such as osteoarthritis will affect an
estimated 18.2% (59.4 million) of Americans. Recent estimates suggest
that total costs associated with arthritis, including osteoarthritis,
may exceed 2% of the gross domestic product. The patent pending LFIT
System represents an extension of existing research that has
demonstrated Pulsed Electromagnetic Stimulation (PES) technologies to be
effective in the treatment of a variety of musculoskeletal pain
conditions, including osteoarthritis. TheraNova has received NonSignificant Risk Status from the FDA and has completed its small pilot clinical study at the University of Utah with trends towards efficacy across a variety of parameters in the WOMAC scale. Contact for details. |
| |
Cardiovascular Anchor (CVA)
Seeking licensing or development partner |
About 50,000 people have open heart surgery every year in the US to replace the aortic valve. This is a highly invasive surgery and involves the painful and complication-ridden sternotomy. In order to avoid this surgery, companies have sprung up to develop an aortic valve that can be delivered percutaneously through the femoral artery. This minimally invasive approach, though, has led to issues related to anchoring of the device with fatalities caused by migration of shifting of the device after implantation. By providing a two-step procedure and using the body's own tissue ingrowth to anchor the device, TheraNova's CVA achieves the best of both worlds by providing both the minimally invasive benefit of percutaneously placed valves and the firm anchoring of a surgically placed valve. Contact for details. |
| |
Dynamic
Vacuum Compression (DVC)
Seeking licensing or development partner |
There are 190 million people in the world today with diabetes. Approximately 20 percent of all persons with diabetes will develop foot ulcers and as many as 50 percent of older type 2 diabetes patients are at risk for foot ulcers. These ulcers are very difficult and costly to treat, frequently leading to amputation of foot or leg. Despite this large market with a desparate need, there is no good solution to aid in the healing of these ulcers. The DVC provides the environment required to heal these ulcers through its application of circumferential negative pressure wound therapy. Early prototypes have shown that the DVC system is capable of providing the environmental conditions required for healing of these problem ulcers. Contact for details. |
| |
Autosterilizing Implant (ASI)
Seeking licensing or development partner |
The most common cause for removal and/or replacement of an implant is infection. This is particularly true for implants that have external communication or that are accessed percutaneously on an intermittent basis, i.e. subcutaneous injection ports (SIPs). These SIPs are placed to provide long-term access to a major vessel in many conditions, one of the most prominent of which is delivery of chemotherapy to treat cancer. These patients are at even greater risk of infection due to their underlying disease and immunosuppression with chemotherapy. The first embodiment of the widely applicable ASI platform, then, provides a means for automated sterilization of an SIP to prevent infectious overgrowth. The ASI component of the port is embodied in a thin, battery-driven, transcutaneously rechargeable device which delivers sterilizing energies on a programmed basis to keep the implant free from infection. Contact for details. |
|
|
| | | |
|
|
